SOLARA ACTIVE PHARMA SCIENCES
|
SOLARA ACTIVE PHARMA SCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -6.16 | -16.15 | 61.62 | 42.69 | 23.09 |
| CEPS(Rs) | 24.71 | 15.01 | 91.85 | 77.72 | 55.53 |
| DPS(Rs) | - | - | 7.00 | 2.00 | 5.00 |
| Book NAV/Share(Rs) | 416.43 | 423.30 | 441.06 | 366.93 | 329.64 |
| Tax Rate(%) | 50.36 | 36.02 | 0.07 | 0.34 | -2.87 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 9.27 | 6.31 | 23.87 | 19.63 | 15.02 |
| EBIT Margin(%) | 3.13 | -1.25 | 18.92 | 14.59 | 9.96 |
| Pre Tax Margin(%) | -3.10 | -7.18 | 13.70 | 8.69 | 4.10 |
| PAT Margin (%) | -1.54 | -4.60 | 13.69 | 8.66 | 4.22 |
| Cash Profit Margin (%) | 6.16 | 4.26 | 20.41 | 15.79 | 10.16 |
| Performance Ratios | |||||
| ROA(%) | -0.78 | -2.13 | 9.34 | 5.57 | 3.14 |
| ROE(%) | -1.47 | -3.75 | 17.23 | 12.48 | 7.36 |
| ROCE(%) | 1.79 | -0.67 | 15.34 | 11.73 | 9.70 |
| Asset Turnover(x) | 0.51 | 0.46 | 0.68 | 0.64 | 0.74 |
| Sales/Fixed Asset(x) | 0.80 | 0.73 | 0.98 | 0.90 | 1.14 |
| Working Capital/Sales(x) | 16.71 | 7.21 | 6.01 | -22.83 | -190.35 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.26 | 1.37 | 1.02 | 1.12 | 0.87 |
| Receivable days | 129.77 | 140.08 | 80.18 | 71.15 | 71.43 |
| Inventory Days | 143.29 | 125.26 | 64.87 | 68.16 | 52.03 |
| Payable days | 134.61 | 163.35 | 132.36 | 140.33 | 140.46 |
| Valuation Parameters | |||||
| PER(x) | - | - | 22.63 | 10.38 | 18.15 |
| PCE(x) | 13.29 | 44.32 | 15.18 | 5.70 | 7.55 |
| Price/Book(x) | 0.79 | 1.57 | 3.16 | 1.21 | 1.27 |
| Yield(%) | - | - | 0.50 | 0.45 | 1.19 |
| EV/Net Sales(x) | 1.51 | 2.66 | 3.35 | 1.39 | 1.09 |
| EV/Core EBITDA(x) | 13.90 | 33.72 | 13.07 | 6.41 | 6.88 |
| EV/EBIT(x) | 48.07 | -213.14 | 17.71 | 9.54 | 10.99 |
| EV/CE(x) | 0.77 | 1.17 | 2.09 | 0.85 | 0.79 |
| M Cap / Sales | 0.82 | 1.89 | 3.10 | 0.90 | 0.77 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 13.83 | -21.56 | 22.33 | -6.16 | 151.35 |
| Core EBITDA Growth(%) | 56.45 | -75.89 | 44.49 | 28.15 | 260.73 |
| EBIT Growth(%) | 385.97 | -105.17 | 58.70 | 37.49 | 452.78 |
| PAT Growth(%) | 61.83 | -126.33 | 93.29 | 92.76 | - |
| EPS Growth(%) | 61.86 | -126.21 | 44.36 | 84.84 | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.67 | 0.67 | 0.38 | 0.72 | 0.63 |
| Current Ratio(x) | 1.08 | 1.17 | 1.34 | 0.92 | 0.99 |
| Quick Ratio(x) | 0.57 | 0.62 | 0.97 | 0.54 | 0.66 |
| Interest Cover(x) | 0.50 | -0.21 | 3.62 | 2.48 | 1.70 |
| Total Debt/Mcap(x) | 0.85 | 0.43 | 0.12 | 0.59 | 0.50 |
Compare Financial Ratios of peers of SOLARA ACTIVE PHARMA SCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SOLARA ACTIVE PHARMA SCIENCES | ₹1,949.9 Cr | 1.5% | 46.2% | 50.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹360,920.0 Cr | -0.1% | -2.8% | 50.3% | Stock Analytics | |
| CIPLA | ₹113,794.0 Cr | 4.5% | -3.1% | 52.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹106,860.0 Cr | 4.7% | 10.8% | 18.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,316.0 Cr | 4.6% | 1.4% | 22.2% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,380.9 Cr | 3.1% | -4.1% | 80.4% | Stock Analytics | |
SOLARA ACTIVE PHARMA SCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SOLARA ACTIVE PHARMA SCIENCES | 1.5% |
46.2% |
50.2% |
| SENSEX | 0.9% |
1.5% |
23.6% |
You may also like the below Video Courses
